Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS by Gibbs, KL et al.
Gibbs et al. Cell Death and Disease
DOI 10.1038/s41419-018-0624-8 Cell Death & Disease
ART ICLE Open Ac ce s s
Inhibiting p38 MAPK alpha rescues axonal
retrograde transport defects in a mouse
model of ALS
Katherine L. Gibbs1, Bernadett Kalmar1, Elena R. Rhymes1, Alexander D. Fellows1, Mahmood Ahmed2, Paul Whiting1,3,4,
Ceri H. Davies2,6, Linda Greensmith1 and Giampietro Schiavo 1,4,5
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by the degeneration of upper and
lower motor neurons. Defects in axonal transport have been observed pre-symptomatically in the SOD1G93A mouse
model of ALS, and have been proposed to play a role in motor neuron degeneration as well as in other pathologies of
the nervous system, such as Alzheimer’s disease and hereditary neuropathies. In this study, we screen a library of small-
molecule kinase inhibitors towards the identiﬁcation of pharmacological enhancers of the axonal retrograde transport
of signalling endosomes, which might be used to normalise the rate of this process in diseased neurons. Inhibitors of
p38 mitogen-activated protein kinases (p38 MAPK) were identiﬁed in this screen and were found to correct deﬁcits in
axonal retrograde transport of signalling endosomes in cultured primary SOD1G93A motor neurons. In vitro knockdown
experiments revealed that the alpha isoform of p38 MAPK (p38 MAPKα) was the sole isoform responsible for
SOD1G93A-induced transport deﬁcits. Furthermore, we found that acute treatment with p38 MAPKα inhibitors restored
the physiological rate of axonal retrograde transport in vivo in early symptomatic SOD1G93A mice. Our ﬁndings
demonstrate the pathogenic effect of p38 MAPKα on axonal retrograde transport and identify a potential therapeutic
strategy for ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease caused by the degeneration of both
upper and lower motor neurons, resulting in progressive
muscle paralysis and ultimately death. Although the pre-
cise cause of motor neuron degeneration in ALS is not yet
fully understood, several mechanisms have been proposed
to play a role in this process, including mitochondrial
dysfunction, excitotoxicity and axonal transport deﬁ-
cits1,2. However, which of these mechanisms play a cau-
sative role in ALS pathogenesis is currently unknown1,2.
Deﬁcits in axonal transport have been inferred from
patient data and observed in ALS mouse models2. In mice
overexpressing the ALS-associated human superoxide
dismutase 1 G93A (SOD1G93A) mutant, intravital imaging
in the sciatic nerve has revealed abnormalities in the
axonal retrograde transport of signalling endosomes and
mitochondria in pre-symptomatic mice3. The deﬁcit in
endosome motility was demonstrated using two inde-
pendent probes: the binding fragment of tetanus toxin
(HCT)
4 and an antibody speciﬁc for the p75 neurotrophin
receptor (αp75NTR)5. The early appearance of transport
impairments in the SOD1G93A mouse model3 suggests
that these deﬁcits play a crucial role in triggering motor
neuron dysfunction, leading to the motor neuron degen-
eration observed in ALS.
Despite the strength of evidence demonstrating the
presence of axonal transport defects in ALS2 and other
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neurodegenerative conditions6,7 a causal relationship
between these transport impairments and neurodegen-
eration has not yet been shown. Indeed, the role of axonal
transport defects in ALS pathogenesis remains a matter of
some debate. Work using an ALS mouse model expres-
sing the SOD1G85R mutant has shown that motor neuron
degeneration can also occur in the absence of overt axonal
transport deﬁcits8, although it should be noted that these
results have been obtained using explants rather than
intravital microscopy, and disease progression is much
more variable in the SOD1G85R mouse model than in the
SOD1G93A mice used in our study3. Hence, the identiﬁ-
cation of compounds able to speciﬁcally enhance axonal
transport and thereby rescue the deﬁcits observed in
SOD1G93A mice would conclusively prove the role of
axonal transport defects in ALS pathogenesis.
Protein kinases have been suggested to be key players in
several neurodegenerative diseases9. It has been proposed
that disease-associated pathological proteins, such as amy-
loid beta (Aβ) and SOD1G93A, mediate their toxic effects
through the activation of speciﬁc kinase cascades10, such
as p38 mitogen-activated protein kinase (MAPK)11–16. In
this study, we demonstrate that p38 MAPK is responsible
for SOD1G93A-induced deﬁcits in axonal retrograde
transport in motor neurons and establish that speciﬁc
inhibition of p38 MAPK alpha (p38 MAPKα) or its down-
regulation corrects axonal transport deﬁcits both in vitro
and in vivo in SOD1G93A mice. Inhibitors of p38 MAPKα
are thus powerful tools to determine the role of axonal
retrograde transport deﬁcits in ALS pathogenesis and
could be explored for future therapeutic intervention.
Results
Screening for pharmacological enhancers of axonal
transport
The accumulation of HCT and α-p75
NTR in mouse
embryonic stem (ES) cell-derived motor neurons has been
previously validated in our laboratory as a biological read-
out capable of identifying novel axonal trafﬁcking effec-
tors when combined with a siRNA screen17,18. In this
study, we adapted this assay to screen a library of kinase
inhibitors to identify novel regulators of axonal retrograde
transport. As before17,18, transgenic HB9-GFP ES cells
(HBG3) differentiated into motor neurons were used to
overcome the intrinsic cellular heterogeneity of primary
motor neuron cultures and obtain the large amount of
neurons required for the screen. The expression of green
ﬂuorescent protein (GFP) driven by the Hb9 homeobox
gene enhancer facilitated the identiﬁcation of motor
neurons and enabled the implementation of a reliable
automatic quantiﬁcation protocol17.
To determine whether this assay was sensitive to
changes in axonal transport efﬁciency, we performed
preliminary tests in the presence of known modulators
of motor proteins involved in this process. Erythro-9-
(2-hydroxy-3-nonyl)adenine (EHNA) is an established
inhibitor of cytoplasmic dynein, and blocks the axonal
retrograde transport of HCT-containing signalling endo-
somes19. Treatment of ES cell-derived motor neurons
with 1 mM EHNA resulted in a signiﬁcant decrease in
HCT or α-p75
NTR accumulation in the soma (Supple-
mentary Fig. 1A-D), indicating that the sensitivity of this
assay is sufﬁcient to detect alterations in axonal retro-
grade transport rates. However, EHNA is not a very
selective inhibitor20,21 and therefore we cannot rule out
the possibility that its effects on the somatic accumulation
of HCT and α-p75
NTR may be due to off-target effects. We
therefore incubated wild-type primary motor neurons
with 50 μM ciliobrevin A, a blocker of the ATPase activity
of cytoplasmic dynein22. In vitro axonal transport assays
revealed a signiﬁcant inhibition of the retrograde trans-
port of HCT-labelled organelles (Fig. 1a), whilst 100 µM
ciliobrevin A caused a complete block of transport.
Importantly, this inhibition of axonal transport was also
mirrored by a signiﬁcant reduction of HCT (Fig. 1b, c) and
α-p75NTR (Fig. 1d, e) accumulation in the soma.
Few speciﬁc enhancers of axonal transport are currently
available. Acetyl-L-carnitine (ALCAR) was previously
reported to enhance axonal retrograde transport in dia-
betic rats23. Accordingly, treatment of ES cell-derived
motor neurons with 1 mM ALCAR increased the retro-
grade transport speed of HCT-labelled organelles in cul-
tured motor neurons (Fig. 1f). We were also consistently
able to detect this increase in transport efﬁciency using
the accumulation assay, with approximately 25–30% more
accumulation of HCT (Fig. 1g,h) and α-p75
NTR (Fig. 1i,j)
in ALCAR-treated motor neurons.
A further validation step for this assay was to conﬁrm
whether this approach could detect the axonal transport
deﬁcits previously observed in SOD1G93A motor neu-
rons24. Using primary motor neurons cultures, we found a
signiﬁcant decrease in HCT accumulation in SOD1
G93A
motor neurons compared to wild-type controls (Supple-
mentary Fig. 1E, F).
Having established that the accumulation assay was
suitable for the detection of changes in axonal retrograde
transport efﬁciency induced both pharmacologically and
by the expression of pathogenic proteins, we used it to
screen a library of small-molecule kinase inhibitors
(Supplementary Table 1). Compounds were initially tested
at a concentration of 2 μM and their effects compared
with vehicle (DMSO). Active compounds were deﬁned
as those that increased the mean staining intensity of
HCT and α-p75
NTR by at least three standard deviations
above the control level (yellow rectangle; Fig. 2a and
Supplementary Fig. 2A), which was taken as 100%. Two
active compounds (A1 and C3) were identiﬁed (Fig. 2a),
representing a primary hit rate of 4%. We also identiﬁed
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three inhibitory molecules (E6, F2 and G6; Fig. 2a), which
however were not investigated further.
We next performed dose–response assays using the
same methodology. In addition to the previously tested
concentration of 2 μM, the assay was also performed at
0.4 and 10 μM (Fig. 2b, c). Two additional compounds
from the initial screen (A4, D3) were included in the
dose–response assays because their effects on HCT and
α-p75NTR accumulation were close to the signiﬁcance
boundary (yellow rectangle; Fig. 2a) and their interesting
pharmacological target (Supplementary Table 1), raising
the possibility that the concentration used in the ﬁrst
screen might have been too low. All four compounds
were found to modulate the accumulation of HCT and
α-p75NTR at doses higher than 0.4 μM (Fig. 2b, c). How-
ever, at 10 μM, these molecules (with the exception of C3)
had either a toxic and/or an inhibitory effect on HCT and
α-p75NTR accumulation (Fig. 2b, c).
Based on the dose–response data, compounds A1 and
C3 were selected for further analyses. Both molecules
were able to correct the deﬁcits in HCT accumulation
observed in SOD1G93A motor neurons when tested at
2 μM (Fig. 2d). However, upon further testing, compound
C3 was also found to cause axonal blebbing (data not
shown) and was therefore excluded from further studies.
Inhibition of p38 MAPK corrects axonal transport defects
in vitro
Compound A1 (SB-239272; CHEMBL275798) is an
inhibitor of p38 MAPK. Interestingly, abnormal activation
of p38 MAPK has been previously implicated in ALS
pathogenesis11–16 and was found to inhibit axonal trans-
port in squid axoplasm12,25. We found that compound A1
at 2 μM was able to correct deﬁcits in the axonal retro-
grade transport of both HCT and α-p75
NTR in SOD1G93A
motor neurons (Fig. 3a–c). In contrast, when applied to
wild-type motor neurons, compound A1 had no effect
(Supplementary Fig. 2B).
To conﬁrm that activated p38 MAPK is a negative
regulator of axonal transport, we next performed live
in vitro axonal transport assays in the presence of 1.9 μM
anisomycin, an activator of p38 MAPK26 (Fig. 3d).
Anisomycin-treated wild-type motor neurons displayed a
strong inhibition of the retrograde transport of HCT
(Fig. 3e), similar to that observed in untreated SOD1G93A
motor neurons (Fig. 3b).
We then tested additional kinase inhibitors in the accu-
mulation assay to further validate p38 MAPK as the target
of compound A1 (Supplementary Table 2). Four chemi-
cally diverse p38 MAPK inhibitors were found to increase
HCT and α-p75
NTR accumulation in ES cell-derived motor
neurons (Supplementary Fig. 3A and Supplementary
Table 3), and correct SOD1G93A-induced deﬁcits in axonal
transport, mimicking the effects of compound A1 (Sup-
plementary Fig. 3B-E). These results strongly suggest that
these compounds normalise axonal retrograde transport in
SOD1G93A motor neurons via the inhibition of p38 MAPK.
p38 MAPK is activated in motor neurons isolated from
SOD1G93A mice
We next investigated whether activated p38 MAPK can
be detected in embryonic primary SOD1G93A motor
neurons. As shown in Fig. 3f, a signiﬁcant activation of
p38 MAPK was found in SOD1G93A motor neuron cul-
tures compared to wild-type controls and motor neurons
overexpressing wild-type human SOD1 (SOD1WT)
(Fig. 3g). We also assessed the levels of activated p38
MAPK in the spinal cords of mice overexpressing either
SOD1G93A or SOD1WT at different disease stages (Sup-
plementary Fig. 4). Pre-symptomatic (36 d), early symp-
tomatic (73 d), symptomatic (96 d) and late symptomatic
(115 d) mice were chosen so that the level of activated p38
MAPK could be directly correlated with the in vivo
axonal transport defects previously described3. p38
MAPK was found to be activated in the spinal cord of pre-
symptomatic SOD1G93A mice compared to wild type
and SOD1WT controls (Supplementary Fig. 4). Crucially,
p38 MAPK activity was highest in early symptomatic
SOD1G93A mice—the age at which in vivo axonal trans-
port defects are most severe3. These data are in agreement
with previous ﬁndings demonstrating activation of p38
MAPK in SOD1G93A mice12,13,15.
Fig. 1 Ciliobrevin A and ALCAR modulate the axonal retrograde transport of HCT in motor neurons. a Speed proﬁles of HCT carriers in motor
neurons treated with DMSO (black squares) or 50 μM ciliobrevin A (red diamonds) (DMSO: 55 carriers, 10 axons; 50 μM ciliobrevin A: 46 carriers, 8
axons; 3 independent experiments). b, c Effects of 100 μM ciliobrevin A on the accumulation of HCT in the cell body of ES cell-derived motor neurons.
ES cell-derived motor neurons were incubated with AlexaFluor 555-conjugated HCT and DMSO or 100 μM ciliobrevin A for 2 h. Cells were then acid-
washed, ﬁxed, imaged and quantiﬁed in C as described below. d, e Effects of 100 μM ciliobrevin A on the accumulation of α-p75NTR in the soma of ES
cell-derived motor neurons. ES cell-derived motor neurons were incubated with α-p75NTR and DMSO or 100 μM ciliobrevin A for 2 h. Cells were then
acid-washed, ﬁxed, permeabilised, stained for α-p75NTR and quantiﬁed in E. f Speed proﬁles of HCT carriers in ES cell-derived motor neurons treated
with control medium (black squares) or 1 mM ALCAR (green triangles) (control: 53 carriers, 10 axons; 1 mM ALCAR: 61 carriers, 8 axons; 3 independent
experiments). g, h Effects of 1 mM ALCAR on accumulation of HCT (g, h) and α-p75
NTR (i, j) in the cell body of ES cell-derived motor neurons. ES cell-
derived motor neurons were treated as described in B-E. The amount of HCT and α-p75
NTR was quantiﬁed as the mean staining intensity per pixel in
the cell body. Results in C, E, H, J are expressed as a percentage of the control ± SEM (n= 3 independent experiments; n ≥ 25 cell bodies analysed per
condition). *** p < 0.001 (unpaired Student’s t-test)
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p38 MAPKα activation causes SOD1G93A-induced deﬁcits in
axonal transport
The four isoforms of p38 MAPK (α, β, γ, δ) are
all expressed in primary motor neurons (Fig. 4a). Because
p38 MAPKs are involved in numerous signalling
pathways, it is crucial to determine which isoform(s) is
responsible for the transport inhibition observed in
SOD1G93A motor neurons. This in turn would provide a
more speciﬁc therapeutic target reducing undesirable
side effects, a problem which has severely hampered the
Fig. 2 Chemical screen for the identiﬁcation of enhancers of HCT and α-p75
NTR accumulation in the soma of ES cell-derived motor neurons.
a The results of a small-molecule chemical screen are shown as an XY plot of the normalized mean staining intensity for α-p75NTR versus AlexaFluor
555-conjugated HCT. α-p75
NTR was detected using an AlexaFluor 647-conjugated donkey anti-rabbit secondary antibody. Active compounds (red
dots) were deﬁned as those able to increase accumulation of α-p75NTR and HCT by at least three times the standard deviation of the dataset
(represented by the yellow rectangle). The negative control (EHNA) is shown in blue (n ≥ 25 cell bodies analysed per condition; n= 3 repeats). b, c
Dose–response analysis of the top four active compounds identiﬁed by the screening displayed in A. The accumulation assay was performed at 0.4, 2
and 10 μM and the amount of HCT (b) and α-p75
NTR (c) in the soma was quantiﬁed as the mean staining intensity per pixel ( ± SEM) (n ≥ 25 cell
bodies per condition, n= 3 repeats). d Effects of 2 μM A1 and C3 on the accumulation of HCT in the cell body of primary motor neurons isolated from
E13 SOD1G93A embryos (DIV6). The amount of HCT was quantiﬁed as described in B, C and shown as mean ± SEM. Signiﬁcance levels were
determined using the Kruskal–Wallis test followed by Dunn’s multiple comparisons test. n= 3 repeats; *** p < 0.001; * p < 0.05
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development of new therapeutic approaches directed
towards p38 MAPK27.
Since p38 MAPKα has been previously shown to reg-
ulate anterograde transport in isolated squid axoplasm12,
we sought to test whether this isoform is responsible for
the defects in axonal retrograde transport observed in
SOD1G93A mice. Lentiviral shRNA vectors expressing GFP
as a reporter were used to knockdown p38 MAPKα in
SOD1G93A motor neurons (Fig. 4b and Supplementary
Fig. 5A) and restored axonal retrograde transport to
physiological wild-type levels (Fig. 4c), mimicking the
results obtained by pharmacological inhibition of p38
MAPK. Transduction of motor neurons with a scrambled
shRNA construct had no effect on p38 MAPKα expression
(Fig. 4d and Supplementary Fig. 5B), or on axonal trans-
port speeds, in either SOD1G93A (Fig. 4c, e) or wild-type
motor neurons (Fig. 4c, f). To conﬁrm that these results
were speciﬁc to p38 MAPKα, we also knocked down p38
MAPKδ (Supplementary Fig. S5C) in SOD1G93A motor
neurons, and observed no effect on axonal retrograde
transport speeds (Supplementary Fig. S5D).
SB-239063 corrects axonal transport defects in vitro and
in vivo
We next looked to conﬁrm the role of p38 MAPKα on
axonal transport in vitro and in vivo using established
pharmacological tools. SB-203580 is an inhibitor of p38
MAPKα and β that has been shown to prevent SOD1G93A-
induced motor neuron death in vitro13. When tested at 2
μM, we found that SB-203580 was able to correct
SOD1G93A-induced deﬁcits in axonal retrograde transport
in vitro (Fig. 5a). However, SB-203580 is also known to
inhibit c-Jun N-terminal protein kinase 2/3 (JNK2/3)28, a
pathway which has been shown to regulate survival in
SOD1E100G human induced pluripotent stem cell (hiPSC)-
derived motor neurons29. Therefore, to demonstrate that
inhibition of JNK2/3 is not involved in the restoration of
axonal retrograde transport, we tested SB-239063, a sec-
ond generation p38 MAPKα and β inhibitor with
enhanced speciﬁcity30. Similarly to SB-203580, SB-239063
was able to rescue axonal transport in vitro in SOD1G93A
motor neuron cultures (Fig. 5b). Importantly, SB-239063
does not affect JNK activity in wild type and SOD1G93A
motor neurons (Fig. 5c, e), whereas p38 MAPK is strongly
inhibited (Fig. 5d,f). This result is in line with our primary
screen (Supplementary Fig. 2A; Supplementary Table 1)
and previous results30 where JNK inhibition had no effect.
Additionally, this compound reduced the hyperpho-
sphorylation of neuroﬁlament heavy chain (Supplemen-
tary Fig. 6A), which occurs in SOD1G93A mice through
increased p38 MAPK activity16.
SB-239063 is also able to cross the blood brain barrier
and pharmacokinetic analysis revealed that an intraper-
itoneal (i.p.) dose of 100mg/kg allowed for circulating
concentrations in the brain, spinal cord and muscle to
reach, albeit transiently, levels similar to those used in our
in vitro axonal transport assays (Supplementary Fig. 5B,
C). Early symptomatic (73 ± 3 d) SOD1G93A mice were
treated with 100 mg/kg SB-239063 (i.p.) and axonal ret-
rograde transport was assessed by imaging the sciatic
nerve 4 h later in live, anaesthetised mice31 (Fig. 6a). This
treatment was able to ameliorate the deﬁcits in axonal
retrograde transport of SOD1G93A mice, restoring trans-
port rates to those observed in wild-type animals
(SOD1G93A untreated versus SOD1G93A+ 100mg/kg SB-
239063: p < 0.0001; Fig. 6b). Similar results were obtained
when the concentration of SB-239063 was reduced to
10mg/kg (data not shown).
Fig. 3 Impaired axonal retrograde transport can by normalised by pre-treatment with a p38 MAPK inhibitor in embryonic SOD1G93A motor
neurons. a Frames from confocal time series of HCT-labelled endosomes in wild type+ DMSO (top), SOD1
G93A+ DMSO (middle) and SOD1G93A+ 2
μM A1 (bottom) axons. Scale bars, 10 μm. b Speed proﬁles of HCT carriers in wild type+ DMSO (black squares), SOD1
G93A+ DMSO (red diamonds)
and SOD1G93A+ 2 μM A1 (blue triangles) motor neuron cultures. Comparison of the curves reveals SOD1G93A motor neurons treated with compound
A1 have a similar speed distribution to wild-type cultures (wild type: 94 carriers, 13 axons; SOD1G93A: 126 carriers, 14 axons; SOD1G93A+ 2 μM A1: 121
carriers, 16 axons; 4 independent experiments; data shown as mean ± SEM). c Speed distribution proﬁles of α-p75NTR carriers in wild type+ DMSO,
SOD1G93A+DMSO (vehicle control) and SOD1G93A+ 2 μM A1 motor neuron cultures (wild type: 118 carriers, 6 axons; SOD1G93A: 85 carriers, 6 axons;
SOD1G93A+ 2 μM A1: 96 carriers, 8 axons; 3 independent experiments; data shown as mean ± SEM). d Treatment of wild-type motor neuron cultures
with 0.5 μg/ml anisomycin (1.9 μM) for 30 min causes a substantial activation of p38 MAPK (upper panel; detected with a phosphospeciﬁc pT180/
pY182 α-p38 MAPK antibody). The total content of p38 MAPK in the samples is shown in the lower panel (pan α-p38 MAPK antibody). e Speed
proﬁles of HCT carriers in motor neuron cultures treated with either DMSO (black squares) or 1.9 μM anisomycin (red diamonds). Anisomycin causes a
shift to slower transport speeds (DMSO treated: 77 carriers, 8 axons; anisomycin treated: 76 carriers, 8 axons; 3 independent experiments; data shown
as mean ± SEM). f Western blot showing activation of p38 MAPK in primary SOD1G93A motor neuron cultures compared to wild-type controls.
Compound A1 normalises phospho-p38 MAPK in SOD1G93A cultures to wild-type levels (top). The upper panel was stained as in panel D.
Quantiﬁcation reveals a 1.5 fold increase in phospho-p38 MAPK in SOD1G93A motor neuron cultures compared to wild-type cells, and conﬁrms the
normalisation of p38 MAPK activity by compound A1 (bottom) (n= 3 independent experiments). Data shown as mean ± SEM. ** p < 0.01, *** p <
0.001 (one-way ANOVA followed by Sidak’s multiple comparison test). gWestern blot showing active p38 MAPK in motor neurons overexpressing the
SOD1WT protein compared to wild-type controls (top). Western blot quantiﬁcation detected no signiﬁcant difference in p38 MAPK activation between
wild-type cultures and motor neurons overexpressing SOD1WT (bottom) (n= 3 independent experiments). Data shown as mean ± SEM. Non-
signiﬁcant (NS) using unpaired Student’s t-test
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Effects of long-term treatment with SB-239063 on muscle
physiology
We next investigated whether long-term treatment with
SB-239063 impacts on ALS progression. SOD1G93A and
wild-type littermates were treated with either 10 mg/kg
SB-239063 or vehicle control (1% methylcellulose) i.p.
twice daily until termination at 90 (symptomatic) and 120
d (end-stage of disease) (Fig. 7a). Hindlimb muscle func-
tion, including maximum tetanic tension in tibialis ante-
rior (TA) and extensor digitorum longus (EDL) muscles,
Fig. 4 (See legend on next page.)
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was determined in live anaesthetised animals at 90 and
120 d. In SOD1G93A mice, TA and EDL muscles become
progressively weaker, losing approximately 30% and 60%
of muscle force at 90 and 120 d, respectively (Fig. 7b).
Treatment with SB-239063 had no signiﬁcant effect on
force production of EDL or TA muscles (Fig. 7b, c).
The number of functional motor units innervating the
EDL muscle in vehicle-treated SOD1G93A mice is sig-
niﬁcantly reduced by 90 d (from 30.8 ± 0.6 in wild-type
mice to 21.2 ± 0.8, p < 0.0001; Fig. 7d), with a further loss
occurring by 120 d (11.3 ± 0.7, p < 0.0001; Fig. 7d). Whilst
treatment with SB-236093 had no effect on motor unit
survival at 90 d (20.0 ± 1.7 motor units; p= 0.79), a sig-
niﬁcant protection was observed at 120 d in SOD1G93A
mice treated with SB-239063 (14.7 ± 1.2 compared to 11.9
± 2 functional motor units in SOD1G93A mice treated with
vehicle control; p= 0.0073; Fig. 7d).
We also examined whether hindlimb muscle innerva-
tion in SOD1G93A mice was affected by long-term treat-
ment with SB-239063 by assessing neuromuscular
junctions (NMJs) in lumbrical muscles. These muscles
innervate the digits of the hindlimbs and are one of the
most distally affected muscle groups in SOD1G93A mice32.
Endplates were scored according to whether they were
fully innervated (arrows), partially innervated (arrow-
heads), or denervated (double arrows; Supplementary
Fig. 7A). At 90 d, more denervated endplates were found
in SOD1G93A (36.4 ± 8.9%) than wild-type mice (9.6 ±
1.6%; p= 0.071). By 120 d, 42.8 ± 2.8% of endplates were
denervated in SOD1G93A mice (p= 0.0062; Supplemen-
tary Fig. 7B). Treatment with SB-239063 had no sig-
niﬁcant effect on preserving muscle innervation in
SOD1G93A mice at both 90 and 12 d (Supplementary
Fig. 7B).
These results show that, with the exception of a mild
protection of EDL motor units at 120 d (Fig. 7d), long-
term treatment with SB-239063 at an early symptomatic
stage of disease did not lead to signiﬁcant functional
improvement in SOD1G93A mice. However, when we
assessed axonal transport in SOD1G93A mice at 90 or 120
d, we found that axonal retrograde transport remained
severely impaired despite the long-term treatment with
SB-239063 (Fig. 7e and Supplementary Fig. 7C, D).
As shown previously3, symptomatic (90 d) and late
symptomatic (120 d) SOD1G93A mice display subtle deﬁ-
cits in axonal transport. This is likely due to the decrease
in ALS-susceptible motor neuron axons observed at late
time points of disease progression, and the increase in the
contribution of ALS-resistant neurons to overall axonal
transport rates. We therefore assessed the effects of long-
term treatment with SB-239063 in pre-symptomatic 70 d
old SOD1G93A mice, the same age at which we found
acute treatment to completely revert transport deﬁcits
(Fig. 6). 50 d old SOD1G93A mice were treated with SB-
239063 (10 mg/kg, twice daily) for 20 d (Supplementary
Fig. 7E). Surprisingly, this treatment regime had very
different effects than an acute treatment, since it failed to
restore axonal transport in SOD1G93A mice (Supplemen-
tary Fig. 7F). This is likely due to overt toxicity of long-
term treatment with SB-239063, which caused sustained
weight loss (Supplementary Fig. 7G), and spleen and liver
toxicity (Supplementary Fig. 7H). The methylcellulose
used as vehicle is likely to have contributed to these side
effects33,34. Additionally, the inability to maintain effective
concentrations of SB-239063 in the brain may have con-
tributed to the lack of long-term improvement of the
SOD1G93A ALS phenotype.
Altogether, these results demonstrate that genetic and
acute pharmacological inhibition of p38 MAPKα is sufﬁ-
cient to reverse the axonal retrograde transport deﬁcits
observed in motor neurons of SOD1G93A mice both
in vitro and in vivo. However, the pharmacology and
formulation of SB-239063 was suboptimal in our experi-
mental design. As a result, long-term treatment with this
p38 MAPK inhibitor, at least in 1% methylcellulose, has
signiﬁcant toxic side effects and, with the exception of a
Fig. 4 p38 MAPKα knockdown normalises axonal retrograde transport in SOD1G93A motor neurons. a Western blot analysis reveals all four
p38 MAPK isoforms (α, β, γ and δ) are expressed in wild type and SOD1G93A motor neuron lysates. Mouse brain lysate was loaded as an antibody
control for p38 MAPKβ. The upper band is only detected in spinal cord extracts and may represent a posttranslational modiﬁed form of p38 MAPKβ.
b Lentiviral delivery of shRNA targeted against p38 MAPKα reduces its levels in primary motor neurons. Transduced motor neurons express GFP. c
Speed proﬁles of HCT-containing signalling endosomes in wild-type motor neurons transduced with scrambled shRNA (black squares), SOD1
G93A
motor neurons transduced with scrambled shRNA (red diamonds) and SOD1G93A motor neurons transduced with p38 MAPKα shRNA (blue triangles).
Axonal transport has been quantiﬁed only in GFP-positive motor neurons. Comparison of the curves reveals that knocking down p38 MAPKα in
SOD1G93A motor neurons (blue triangles) accelerates axonal transport to wild-type speeds (black squares) (wild type+ scrambled shRNA: 89 carriers,
17 axons; SOD1G93A+ scrambled shRNA: 104 carriers, 24 axons; SOD1G93A+ p38 MAPKα shRNA: 99 carriers, 20 axons; 4 independent experiments). d
Lentiviral delivery of scrambled shRNA has no effect on levels of p38 MAPKα in primary motor neurons. Transduced motor neurons express GFP. e
Speed proﬁles of HCT carriers in untreated SOD1
G93A motor neurons (green circles) and SOD1G93A motor neurons transduced with scrambled shRNA
(scram; red diamonds). Comparison of the curves reveals that the scrambled shRNA construct (red diamonds) has no effect on axonal transport
speeds (SOD1G93A untreated: 45 carriers, 7 axons; SOD1G93A+ scrambled shRNA: 104 carriers, 24 axons; 4 independent experiments). f Speed proﬁles
of HCT carriers in untreated wild-type motor neurons (green circles) and wild-type motor neurons transduced with scrambled shRNA (scram; black
squares). Comparison of the curves reveals that scrambled shRNA constructs have no effect on axonal transport speeds (wild-type untreated: 62
carriers, 5 axons; wild type+ scrambled shRNA: 89 carriers, 17 axons; 3 independent experiments)
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Fig. 5 Rescue of axonal transport deﬁcits in SOD1G93A motor neurons is independent of JNK inhibition. a Speed proﬁles of HCT carriers in
wild-type motor neurons treated with DMSO (black squares), SOD1G93A motor neurons treated with DMSO (red diamonds) and SOD1G93A motor
neurons treated with 2 μM SB-203580 (blue triangles). Comparison of the curves reveals SOD1G93A motor neurons treated with 2 μM SB-203580 have
a similar speed distribution to wild-type cultures (wild type: 134 carriers, 16 axons; SOD1G93A: 112 carriers, 12 axons; SOD1G93A+ 2 μM SB-203580: 75
carriers, 10 axons; 3 independent experiments). b Speed distribution proﬁles of HCT carriers in wild-type motor neurons treated with DMSO (black
squares), SOD1G93A motor neurons treated with DMSO (red diamonds) and SOD1G93A motor neurons treated with 2 μM SB-239063, a p38 MAPKα and
β speciﬁc inhibitor (blue triangles). Comparison of the speed proﬁles reveals SOD1G93A motor neurons treated with 2 μM SB-239063 have a similar
speed distribution curve to wild-type cultures (wild type: 134 carriers, 16 axons; SOD1G93A: 112 carriers, 12 axons; SOD1G93A+ 2 μM SB-239063: 85
carriers, 9 axons; 3 independent experiments). c–f The rescue of deﬁcits in the axonal transport of signal endosomes by SB-239063 is independent of
JNK inhibition. Wild type (WT) and SOD1G93A motor neuron lysates were blotted and stained for active phosphorylated JNK (p-JNK) and for total JNK
(c). The ratio of these signals shown in (e) is not signiﬁcantly affected by treatment with 2 μM SB-239063. These samples were stained for
phosphorylated p38 MAPK (p-p38 MAPK), total p38 MAPKα and GAPDH as loading control (d). The ratio of p-p38 MAPK / total p38 MAPKα signals
shown in (f) reveals a signiﬁcant inhibition of p38 MAPK upon SB-239063 treatment even in conditions maximising p38 MAPK activation (0.5 μ./ml
anisomycin for 60 min; see Fig. 3). n= 3 independent experiments; data shown as mean ± SEM. *, p < 0.05 (two-way ANOVA)
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mild protection of EDL motor units, consequently failed
to improve either axonal transport or muscle function in
SOD1G93A mice.
Discussion
Deﬁcits in axonal transport have been implicated in the
pathogenesis of several neurodegenerative diseases. In
ALS, defects in both anterograde2,3,12 and retrograde2,3,24
axonal transport have been observed at early stages of
disease. This suggests that abnormalities in this pathway
may play a role in the initiation and/or early progression
of ALS. However, to directly demonstrate a role for axonal
transport deﬁcits in triggering neurodegeneration, it is
necessary to show that restoring axonal transport alters
disease progression. The ﬁndings reported in this study
identify pharmacological inhibitors of p38 MAPKα that
are capable of reversing the transport deﬁcits observed in
SOD1G93A motor neurons and thereby provide a valuable
opportunity to establish whether ameliorating transport
deﬁcits modiﬁes disease progression in ALS. However, we
were unable to conclusively test this hypothesis because
long-term in vivo treatment of SOD1G93A mice with SB-
239063 in 1% methylcellulose i.p caused overt liver and
spleen toxicity.
Although defects in axonal transport have been pre-
viously shown in SOD1G93A motor neurons3,24, the
molecular mechanism responsible for these deﬁcits is
currently unknown. Since several kinases have been
linked to axonal transport regulation35 and kinase over-
activation has been suggested to be a pathological hall-
mark of ALS35,36, we screened a library of kinase
inhibitors for enhancers of axonal retrograde transport in
motor neurons. We found that p38 MAPK inhibitors were
able to completely restore axonal transport of signalling
endosomes in primary SOD1G93A motor neurons (Fig. 3),
whilst having no effect on transport speeds in wild-type
cells (Supplementary Fig. 2). These results suggest that
SOD1G93A causes the sustained activation of the p38
MAPK signalling cascade (Fig. 3 and (Supplementary
Fig. 4), which drives the pathological effects of mutant
SOD1 on axonal transport. Interestingly, we observed a
disease-dependent increase in p38 MAPK activation in
SOD1G93A, but not in SOD1WT mice (Fig. 3 and (Sup-
plementary Fig. 4), which correlated with the appearance
and severity of axonal retrograde transport defects3.
Supporting this evidence, other groups have previously
demonstrated activation of p38 MAPK in spinal cords
of both familial and sporadic ALS patients14 and in
SOD1E100G hiPSC-derived motor neurons29.
p38 MAPKα inhibits axonal anterograde transport
through direct phosphorylation of kinesin-112, thus
reducing the ability of the motor to move along axonal
microtubules. In our study, we found that p38 MAPKα
inhibitors restore deﬁcits in axonal retrograde transport,
suggesting a model in which one or more subunits of
cytoplasmic dynein or motor adaptors, are regulated by
phosphorylation35,37,38, as previously reported for hun-
tingtin39 and Ndel140.
The p38 MAPK-mediated inhibition of axonal transport
may also be indirect. p38 MAPKα phosphorylates the
medium and heavy neuroﬁlament subunits (NFM and
NFH), and colocalises with phosphorylated neuroﬁla-
ments in SOD1G93A motor neurons11. Aberrant hyper-
phosphorylation of neuroﬁlaments has been proposed to
slow their transport and induce bundling41, which in turn
may lead to the deﬁcits of axonal transport observed in
ALS. Furthermore, tau is a known substrate of p38 MAPK
and has been shown to be hyperphosphorylated at a pre-
symptomatic stage in SOD1G37R mice42. Phosphorylation
Fig. 6 Inhibition of p38 MAPK correct axonal transport defects
in vivo in SOD1G93A mice. a Mice were anesthetised and AlexaFluor
555-conjugated HCT was injected intramuscularly (i.m.) into the tibialis
anterior (TA) and gastrocnemius muscles (GC). At the same time, 100
mg/kg SB-239063 or vehicle control was administered via
intraperitoneal injection (i.p.). The animals were allowed to recover for
4 h, then re-anesthetised and axonal transport imaged in the exposed
sciatic nerve. b Axonal retrograde transport in single axons of the
sciatic nerve was assessed in 73 d wild type (black triangles), SOD1G93A
(red diamonds) and SOD1G93A mice treated with 100mg/kg SB-
239063 (blue triangles). SOD1G93A mice displayed a signiﬁcant
impairment in axonal retrograde transport (p < 0.0001; Kruskal–Wallis
test, followed by Dunn’s multiple comparison test) compared to wild
type, whilst SOD1G93A mice treated with SB-239063 showed transport
speeds similar to those of wild-type mice (p= 0.5) (wild type: 161
carriers, n (animals)= 4; SOD1G93A: 185 carriers, n= 5; SOD1G93A+
100mg/kg SB-239063: 238 carriers, n= 4; data shown as mean ± SEM).
Treatment of SOD1G93A mice with vehicle was found to have no effect
on in vivo axonal transport speeds
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of tau by p38 MAPK decreases its association with
microtubules43, which was proposed to induce micro-
tubule destabilisation and disruption of axonal transport.
In our study, treatment with SB-239063 decreases
NFH hyperphosphorylation, thus demonstrating target
engagement in vitro. However, since this effect was only
observed after 24 h of treatment (Supplemental Fig. 6), it
may not be the main mechanism underlying the effects of
SB-239063 on axonal transport.
Although some controversy exists regarding the role
of axonal transport deﬁcits in ALS8,44, a large body of
evidence indicates that restoring axonal transport could
be a promising therapeutic strategy. For example, phar-
macological inhibition or knockout of histone deacetylase
6 (HDAC6) accelerates axonal transport in motor
and sensory neurons45–47, causing an improvement in
motor behaviour in a peripheral neuropathy model47, and
increasing motor neuron survival and lifespan in
SOD1G93A mice48. In addition, the p38 MAPKα and β
inhibitor SB-203580, shown in this study to restore
axonal transport, reduces SOD1G93A motor neuron death
in vitro13.
Fig. 7 Effects of long-term treatment with SB-239063 on distal hindlimb muscle function and axonal transport. a Timeline of treatment of
SOD1G93A mice with SB-239063. Mice were injected i.p. with 10 mg/kg SB-239063 twice daily until the day of experimentss. b Maximum tetanic force
by extensor digitorum longus (EDL) muscles in response to tetanic stimulation, measured at 90 and 120 d of age (minimum of ﬁve mice in each
experimental group). Data shown as mean ± SEM. ** p < 0.01 (two-way ANOVA with Tukey’s multiple comparison test). c Maximum tetanic force
measured in the TA muscles in response to tetanic stimulation, assessed at 90 and 120 d of age (minimum of six mice in each experimental group).
Data shown as mean ± SEM. Ns, not signiﬁcant; ** p < 0.01 (two-way ANOVA with Tukey’s multiple comparison test). d The number of motor units
innervating the EDL muscle, assessed at 90 and 120 d (minimum of six mice in each experimental group). Treatment with SB-239063 induced a mild
protection of EDL motor units at 120 d. Data shown as mean ± SEM. ** p < 0.01 (two-way ANOVA with Tukey’s multiple comparison test). e The
axonal transport of AlexaFluor 555-conjugated HCT cargoes was measured in live anaesthetized mice at 90 d (wild type: 102 carriers n (animals)= 5;
SOD1G93A+ vehicle: 98 carriers, n= 4; SOD1G93A+ 100mg/kg SB-239063: 124 carriers, n= 4; data shown as mean ± SEM)
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A p38 MAPK inhibitor used in this study, SB-239063, is
potentially suitable for in vivo use, since it is able to cross
the blood brain barrier (Supplementary Fig. 6) and restore
axonal transport in SOD1G93A mice (Fig. 6). In principle,
SB-239063 therefore holds potential to assess whether
axonal transport defects play a signiﬁcant role in the
pathogenesis of ALS. However, optimisation of alternative
formulations and/or treatment regimes are necessary to
overcome the general toxicity found upon i.p adminis-
tration. Although transgenic mice overexpressing human
SOD1G93A are the best-characterised model of ALS to
date49, there are now several familial ALS models avail-
able50,51. Validating our results in other ALS models will
allow us to determine whether inhibition of p38 MAPKα
represents a general therapeutic strategy for ALS or if p38
MAPK overactivation is a pathological mechanism spe-
ciﬁc for mutant SOD1.
Deﬁcits in axonal transport have been shown to be a
hallmark of other neurodegenerative diseases2,7,52,
including Alzheimer’s disease (AD) and hereditary neu-
ropathies. Henceforth, the identiﬁcation of novel enhan-
cers of axonal transport could yield novel therapeutic
approaches for these presently untreatable pathologies.
Interestingly, the p38 MAPKα selective inhibitor MW01-
18-150SRM has been found to attenuate disease pro-
gression in two AD mouse models53, suggesting that
pathological mechanisms may be shared among distinct
neurodegenerative diseases.
Materials and methods
Animals and tissue collection
All experiments were carried out following the guide-
lines of the UCL-Institute of Neurology Genetic Manip-
ulation and Ethic Committees and in accordance with the
European Community Council Directive of November 24,
1986 (86/609/EEC). Animal experiments were undertaken
under license from the UK Home Ofﬁce in accordance
with the Animals (Scientiﬁc Procedures) Act 1986
(Amended Regulations 2012) and the GSK Policy on the
Care, Welfare and Treatment of Animals. Female trans-
genic mice carrying a human wild-type SOD1 (B6SJLTg
[SOD1]2Gur/J) or mutant SOD1G93A (TgN[SOD1-G93A]
1Gur) gene were used in these experiments. Colonies
were maintained by breeding male heterozygous carriers
with female (C57BL/6 × SJL) F1 hybrids. Mice were gen-
otyped for the human SOD1 transgene from ear or tail
genomic DNA. Spinal cords were harvested from term-
inally anaesthetized mice at different stages of disease
progression, snap-frozen in liquid nitrogen and stored
at −80 °C.
Female mutant SOD1G93A mice at different ages (25 or
70 d) were randomly allocated into vehicle treated (1%
methylcellulose; Sigma 274429, St Louis, MO) and SB-
239063 (GlaxoSmithKline, Singapore, SG) treated groups.
A separate group of wild-type mice was also included,
which was treated with vehicle. Mice were injected
intraperitoneally twice daily with 10mg/kg SB-239063
until the day of experiment. In each experimental group
and assessment, 5–8 mice were included.
Motor neuron cultures
ES cell-derived motor neurons were cultured as pre-
viously described17. Primary motor neurons were isolated
from spinal cords of E12.5–13.5 mouse embryos54. Brieﬂy,
embryos were sacriﬁced, the spinal cords dissected and
the ventral horns isolated and dissociated by incubation
with trypsin, followed by incubation with DNase and
centrifugation through a BSA cushion. The resulting cell
pellet was resuspended in complete motor neuron med-
ium [Neurobasal (ThermoFisher, Waltam, MA), 2% v/v
B27 supplement (ThermoFisher), 2% heat inactivated
horse serum, 1% GlutaMAX (ThermoFisher), 25 μM β-
mercaptoethanol, 10 mg/ml recombinant rat CNTF (R&D
Systems, Minneapolis, MN), 100 pg/ml recombinant rat
GDNF (R&D Systems), 1 ng/ml recombinant human
BDNF (R&D Systems) and Pen/Strep antibiotics]. Cells
were immediately plated on poly-DL-ornithine/laminin
coated plates and maintained in culture for 5–8 d (5–8
DIV).
Accumulation and in vitro axonal retrograde transport
assays
The accumulation of AlexaFluor 555-conjugated HCT
and α-p75NTR in the cell body of motor neurons was
performed as previously described17, except that the
HCT and α-p75
NTR were applied in complete medium.
Internalised probes were quantiﬁed using the Cell Proﬁler
software17,18. For drug treatments, compounds were dis-
solved in dimethylsulphoxide (DMSO) and were applied
at the same time as the HCT and α-p75
NTR.
Axonal retrograde transport assays with AlexaFluor
647-conjugated HCT and α-p75
NTR were performed as
previously described55 and quantiﬁed using Motion
Analysis software (Kinetic Imaging, Nottingham, UK).
Compounds were applied at the same time as HCT or
α-p75NTR, and the speed distribution proﬁles of their
carriers have been obtained using a 0.2 μm/s binning
interval3.
Reagents and antibodies
Chemicals were from Sigma-Aldrich, unless otherwise
stated. SB-239272, SB-239063 and SB-203580 were from
GlaxoSmithKline; ciliobrevin A was from InterBioScreen
(Chernogolovka, RU). Tissue culture media and supple-
ments were purchased from Life Technologies. Anti-
bodies for phospho-p38 MAPK (Thr180/Tyr182; #4511),
p38 MAPKα (#9211), p38 MAPKγ (#2307), p38 MAPKδ
(#2308), pan-p38 MAPK (#9212) and JNK (#9252) were
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from Cell Signalling (Danvers, MA). p38 MAPKβ (PA1-
41154) was from ThermoFisher and phospho-JNK (g-7;
#sc-6254) was from Santa Cruz Biotechnology (Dallas,
TX). The GAPDH antibody (mab374) was from Merck
Millipore (Billerica, MA). The mouse monoclonal anti-
body speciﬁc for phosphorylated neuroﬁlament heavy
chain (SMI34; #835503) was from Biolegend (San Diego,
CA). The antibody for GFP (4E12/8) was a kind gift from
the Cancer Research UK London Research Institute
monoclonal facility. The polyclonal antibody against the
extracellular domain of p75NTR (α-p75NTR; 5411) used in
this study has been previously described5.
Lentivirus preparation and transduction
shRNA constructs directed against p38 MAPKα
(MSH030695-LVRU6GP) and δ (MSH0306954-LVRU6GP)
and scrambled controls were purchased from the Omic-
sLink™ shRNA clone collection (GeneCopoeia, Rockville,
MD). All constructs were in psi-LVRU6GP plasmids
with an eGFP reporter gene. Brieﬂy, Lenti-X 293 T cells
(ClonTech, Mountain View, CA) were co-transfected with
shRNA, packaging, and envelope plasmid vectors using
Lipofectamine 3000 (ThermoFisher). Medium containing
lentiviral particles was collected every day for 3 d after
transfection. Medium containing viral particles was con-
centrated using LentiX Concentrator (ClonTech) and
the lentiviral particles resuspended in complete motor
neuron medium. The lentivirus titre was determined
using the Lenti-X p24 Rapid Titre kit (ClonTech) and
lentiviral particles were stored at −80 °C until further
use. To transduce motor neurons, lentivirus was added
to the culture medium 6 h after plating. The medium was
replaced 16 h after transduction, and motor neurons were
assayed one week later.
Western blotting
Motor neuron and spinal cord lysates were prepared in
RIPA buffer (50 mM Tris-HCl pH 7.5, 150mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM
EDTA, 1 mM EGTA) containing Halt™ phosphatase and
protease inhibitor cocktail (1 in 100; ThermoFisher) and
let to incubate on ice for at least 30 min. Lysates
were centrifuged at 14,800 rpm for 15min at 4 °C and
protein concentration determined using Pierce™ BCA
Protein Assay (ThermoFisher). Samples (20 µg) were run
on 4–12% NuPAGE Bis-Tris gradient gels (Thermo-
Fisher) and proteins blotted onto polyvinylidene ﬂuoride
(PVDF) membranes (Merck Millipore). Membranes were
blocked in 5% bovine serum albumin (BSA) dissolved in
Tris-buffered saline (TBS) containing 0.5% Tween-20
(TBST) for 1 h at 4 °C and then incubated with primary
antibodies overnight at 4 °C. Blots were washed and
incubated with appropriate horseradish peroxidase
(HRP)-conjugated secondary antibodies (GE Healthcare,
Little Chalfont, UK). Immunoreactivity was detected
using Crescendo ECL substrates (Merck Millipore) and
FujiFilm X-ray ﬁlm (ThermoFisher). Quantiﬁcation was
performed using ImageJ. For the analysis of neuroﬁlament
phosphorylation, motor neurons (7 DIV) were treated for
either 2 h or 24 h with 2 µM SB-239063 or vehicle control
(DMSO). Five micrograms of protein lysates were run on
a 7.5% acrylamide gels, blotted onto PVDF membranes
and then stained with a mouse monoclonal speciﬁc for
phosphorylated NFH (SMI34).
Immunoﬂuorescence
Motor neurons were ﬁxed in 4% paraformaldehyde in
phosphate buffered saline (PBS) for 15min at room
temperature, permeabilized with 0.1% Triton X-100 in 5%
BSA in PBS for 60 min and then incubated with the
relevant primary antibodies in blocking solution (5% BSA
in PBS) overnight at 4 °C. Motor neurons were washed in
blocking solution and then incubated with the appropriate
secondary antibodies (1:400 in blocking solution). Cells
were washed in PBS, mounted in Mowiol 4–88 and
imaged using a Zeiss LSM 780 confocal microscope
equipped with a 63 × oil-immersion objective (Zeiss,
Oberkochen, DE).
In vivo axonal retrograde transport assays
In vivo axonal transport assays were performed as
previously described3,31. Brieﬂy, mice were anesthetized
with isoﬂurane (National Veterinary Services, Stoke-on-
Trent, UK), and AlexaFluor 555-conjugated HCT (13 μg)
and BDNF (50 ng) were injected intramuscularly into the
exposed TA and gastrocnemius (GC) muscles of one hind
leg, and the wound sutured. Mice were then left to recover
and kept under standard conditions with unlimited
food and water supply. Four hours later, animals were re-
anesthetized and the sciatic nerve exposed. Mice were
placed on a heated stage in an environmental chamber
(both kept at 37 °C) and axonal transport was imaged
in the intact sciatic nerve by time-lapse confocal micro-
scopy. Images of axons were acquired every 3–4 s with an
inverted Zeiss LSM 780 equipped with a 63 × oil-immer-
sion objective (Zeiss, Oberkochen, DE). SB-239063
was suspended in a solution of 1% methylcellulose and
delivered by intraperitoneal injection at the same time
as the AlexaFluor555-conjugated HCT was injected
intramuscularly.
Assessment of muscle force, number of motor units and
endplate innervation
Experimental animals were anesthetised using iso-
ﬂurane on the day of assessment. The distal tendon of the
TA and EDL muscles was dissected and connected to a
force transducer, and the exposed sciatic nerve was
attached to a stimulating electrode. Maximum tetanic
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force as well as the number of functional motor units were
assessed as previously described56.
At the end of the axonal transport experiments, animals
were euthanized and the lumbrical muscles were removed
from the hind paws, ﬁxed in 4 % paraformaldehyde for
5 min and then stained with a combination of antibodies
against neuroﬁlament (2HG3) and SV2 (both from
Developmental Studies Hybridoma Bank, Iowa City, IA)
as well as with AlexaFluor 568-labelled bungarotoxin
(BTX; ThermoFisher)57. Endplate occupancy was scored
according to the level of co-localisation between the
endplate (visualized by BTX labelling) and terminal motor
axon (combined neuroﬁlament and SV2 labelling). End-
plates were classiﬁed into three categories: fully inner-
vated, partially innervated or denervated, according to the
overlap of endplate labelling with the neuroﬁlament/
SV2 staining. For each animal a total of minimum 100
endplates were analysed from different regions of the
muscle to include endplates innervated by multiple
terminal motor axons. Innervation was then expressed as
a percentage of total number of endplates assessed.
Statistical analysis
Statistical analysis was performed using Graphpad
Prism software (La Jolla, CA). Unless otherwise stated,
data is expressed as mean ± SEM. To determine the most
appropriate statistical test to use, data were tested for
normality using three tests: D’Agostino & Person omnibus
normality test, Shapiro-Wilk normality test and KS nor-
mality test. If the data were found to be normally dis-
tributed, either a Student’s t-test (n= 2 groups to
compare) or one-way/two-way analysis of variance
(ANOVA) (n > 2 groups to compare), followed by Dun-
nett’s or Sidak’s multiple comparisons test, was used.
Muscle physiology data were analysed using a two-way
ANOVA with Tukey’s multiple comparisons test. If the
data were not found to be normally distributed, a
Kruskal–Wallis test was used, followed by Dunn’s multi-
ple comparison test (n > 2 groups to compare). If there
were too few data points to accurately test for normality,
data were assumed to be normally distributed. The test
used and associated p values are indicated in the ﬁgure
legends.
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